These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 22687788

  • 21. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
    Dalery J, Honig A.
    Hum Psychopharmacol; 2003 Jul; 18(5):379-84. PubMed ID: 12858325
    [Abstract] [Full Text] [Related]

  • 22. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Fabre L, Birkhimer LJ, Zaborny BA, Wong LF, Kapik BM.
    Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
    [Abstract] [Full Text] [Related]

  • 23. Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases.
    Horii A, Uno A, Kitahara T, Mitani K, Masumura C, Kizawa K, Kubo T.
    J Vestib Res; 2007 Jun; 17(1):1-8. PubMed ID: 18219099
    [Abstract] [Full Text] [Related]

  • 24. The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine.
    Demisch K, Demisch L, Nickelsen T, Rieth R.
    J Neural Transm; 1987 Jun; 68(3-4):257-70. PubMed ID: 3104537
    [Abstract] [Full Text] [Related]

  • 25. Sleep changes during long-term treatment of depression with fluvoxamine--a home-based study.
    Wilson SJ, Bell C, Coupland NJ, Nutt DJ.
    Psychopharmacology (Berl); 2000 May; 149(4):360-5. PubMed ID: 10867963
    [Abstract] [Full Text] [Related]

  • 26. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
    Mundo E, Guglielmo E, Bellodi L.
    Int Clin Psychopharmacol; 1998 Sep; 13(5):219-24. PubMed ID: 9817627
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [Abstract] [Full Text] [Related]

  • 28. Fluvoxamine for somatoform disorders: an open trial.
    Noyes R, Happel RL, Muller BA, Holt CS, Kathol RG, Sieren LR, Amos JJ.
    Gen Hosp Psychiatry; 1998 Nov; 20(6):339-44. PubMed ID: 9854645
    [Abstract] [Full Text] [Related]

  • 29. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study.
    Moresco RM, Colombo C, Fazio F, Bonfanti A, Lucignani G, Messa C, Gobbo C, Galli L, Del Sole A, Lucca A, Smeraldi E.
    Neuroimage; 2000 Oct; 12(4):452-65. PubMed ID: 10988039
    [Abstract] [Full Text] [Related]

  • 30. [Fluoxetine versus fluvoxamine for treatment of chronic pain].
    Ciaramella A, Grosso S, Poli P.
    Minerva Anestesiol; 2000 Oct; 66(1-2):55-61. PubMed ID: 10736983
    [Abstract] [Full Text] [Related]

  • 31. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
    Naito S, Sato K, Yoshida K, Higuchi H, Takahashi H, Kamata M, Ito K, Ohkubo T, Shimizu T.
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
    [Abstract] [Full Text] [Related]

  • 32. [Clinical effectiveness and safety of paroxetine in post-stroke depression: results from a phase 4, open label, multicenter clinical trial with 26 weeks of follow-up].
    Horváth S, Karányi Z, Harcos P, Nagy Z, Németh G, Andor G.
    Orv Hetil; 2006 Dec 17; 147(50):2397-404. PubMed ID: 17274185
    [Abstract] [Full Text] [Related]

  • 33. [Pharmacological and clinical aspects of fluvoxamine (Depromel), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan].
    Hachisu M, Ichimaru Y.
    Nihon Yakurigaku Zasshi; 2000 May 17; 115(5):271-9. PubMed ID: 10872178
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
    Higuchi H, Sato K, Yoshida K, Takahashi H, Kamata M, Otani K, Yamaguchi N.
    Psychiatry Clin Neurosci; 2008 Jun 17; 62(3):301-6. PubMed ID: 18588590
    [Abstract] [Full Text] [Related]

  • 40. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
    Kishi T, Kitajima T, Ikeda M, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Ozaki N, Iwata N.
    Neuropsychobiology; 2009 Jun 17; 59(4):234-8. PubMed ID: 19571598
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.